10-Q/A

              U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON,
                                   D.C. 20549

                                  FORM 10-Q/A
                                AMENDMENT NO. 1

(Mark One)
( X )     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934.

                For the quarterly period ended November 30,2010

                                       OR

(   )     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934.

              For the transition period from ________ to ________.

                         Commission File Number 0-12305

                            REPRO-MED SYSTEMS, INC.
             (Exact name of registrant as specified in its charter)

             New York                                     13-3044880
(State or other jurisdiction of                (IRS Employer Identification No.)
 incorporation or organization)

24 Carpenter Road, Chester New York                         10918
(Address of principal executive offices)                  (Zip Code)

       Registrant's telephone number, including area code: (845) 469-2042

              (Former name, former address and former fiscal year,
                         if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files.) Yes [ ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer   [ ]                        Smaller reporting company [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of November 30, 2010, 36,536,667 shares of common stock, $.01 par value per
share, were outstanding.



                                EXPLANATORY NOTE

Repro-Med Systems, Inc. (the "Company") is filing this Amendment No. 1 on Form
10-Q/A ("Amendment No. 1") to amend Part II, Item 6 of its Quarterly Report on
Form 10-Q for the quarterly period ended November 30, 2010, originally filed
with the Securities and Exchange Commission on January 14, 2011 (the "Original
Quarterly Report"). Repro-Med Systems, Inc. is filing this Amendment No. 1 for
the sole purpose of amending the wording of Exhibit 31.1 of the Original
Quarterly Report, which did not exactly match the wording required by Item
601(b)(31).

Except as described above, this Amendment No. 1 does not modify or update the
disclosures presented in, or exhibits to, the Original Quarterly Report in any
way. Those sections of the Original Quarterly Report that are unaffected by this
Amendment No. 1 are not included herein. This Amendment No. 1 continues to speak
as of the date of the Original Quarterly Report. Furthermore, this Amendment
does not reflect events occurring after the filing of the Original Quarterly
report. Accordingly, this Amendment should be read in conjunction with the
Original Quarterly Report, as well as the Company's other filings made with the
SEC pursuant to Section 13(a) or 15(d) of the Exchange Act subsequent to the
filing of the Original Quarterly Report.

PART II - OTHER INFORMATION
- ---------------------------

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
- -----------------------------------------

(a) EXHIBITS

    31.1  Certification of Chief Executive Officer and Principal Financial
          Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

    32.1  Certification of Chief Executive Officer and Principal Financial
          Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 *
__________________
* previously filed

                                     Page 2


SIGNATURES
- ----------

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934 the Registrant has duly caused this report to be signed on its
behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon                             March 1, 2011
Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, Chief Executive Officer
and Principal Financial Officer

                                     Page 3

EX-31

                                  EXHIBIT 31.1

                           CERTIFICATION PURSUANT TO
                 SECTION 302 OF THE SARBANES-OXLEY ACTS OF 2002

I, Andrew I. Sealfon, certify that:

1)  I have reviewed the Form 10-Q of Repro-Med Systems, Inc. (the "Report");

2)  Based on my knowledge, this report does not contain any untrue statement of
    a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements
    were made, not misleading with respect to the period covered by this report;

3)  Based on my knowledge, the financial statements, and other financial
    information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the
    registrant as of, and for, the periods presented in this report;

4)  The registrant's other certifying officer(s) and I are responsible for
    establishing and maintaining disclosure controls and procedures (as defined
    in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
    financial Reporting (as defined in Exchange Act Rules 13a-15(f) and
    15d-15(f)) for the registrant and have:

    (a) Designed such disclosure controls and procedures, or caused such
        disclosure controls and procedures to be designed under our supervision,
        to ensure that material information relating to the registrant,
        including its consolidated subsidiaries, is made known to me by others
        within those entities, particularly during the period in which this
        report is being prepared;

    (b) Designed such internal control over financial reporting, or caused such
        internal control over financial reporting to be designed under our
        supervision, to provide reasonable assurance regarding the reliability
        of financial reporting and the preparation of financial statements for
        external purposes in accordance with generally accepted accounting
        principles;

    (c) Evaluated the effectiveness of the registrant's disclosure controls and
        procedures and presented in this report our conclusions about the
        effectiveness of the disclosure controls and procedures, as of the end
        of the period covered by this report based on such evaluation; and

    (d) Disclosed in this report any change in the registrant's internal control
        over financial reporting that occurred during the registrant's most
        recent fiscal quarter (the registrant's fourth fiscal quarter in the
        case of an annual report) that has materially affected, or is reasonably
        likely to materially affect, the registrant's internal control over
        financial reporting; and

5)  The registrant's other certifying officer(s) and I have disclosed, based on
    our most recent evaluation of internal control over financial reporting, to
    the registrant's auditors and the audit committee of the registrant's board
    of directors (or persons performing the equivalent functions):

    (a) All significant deficiencies and material weaknesses in the design or
        operation of internal control over financial reporting which are
        reasonably likely to adversely affect registrant's ability to record,
        process, summarize and report financial information; and

    (b) Any fraud, whether or not material, that involves management or other
        employees who have a significant role in the registrant's internal
        control over financial reporting.

Date: March 1, 2011

/s/ Andrew I. Sealfon
Andrew I. Sealfon
Chief Executive Officer and Principal Financial Officer